KQ-2512

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameKQ-2512
Drug Alias NameKQ-2512
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapy
Mechanisms of ActionAnti-BCMAAnti-CD19
TargetsB-cell maturation proteinB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A